Bronchiolitis Obliterans Syndrome Market Report 2026

Bronchiolitis Obliterans Syndrome Market Overview

• Bronchiolitis Obliterans Syndrome market size has reached to $1.59 billion in 2025 • Expected to grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: The Growing Number Of Lung Transplantations Is Fueling The Growth Of The Market Due To The Rising Need To Treat Advanced Respiratory Conditions And Improve Patient Outcomes • Market Trend: Advancements In At-Home Nebulized Therapies Accelerate Treatment For Bronchiolitis Obliterans Syndrome • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Bronchiolitis Obliterans Syndrome Market?

Bronchiolitis obliterans syndrome (BOS) is a chronic and progressive lung disorder marked by inflammation and scarring that narrows the small airways. It often arises as a complication following lung or stem cell transplantation, indicating chronic graft rejection. Early detection of BOS is crucial for prompt treatment to slow its progression and help maintain lung function. The main treatment types of bronchiolitis obliterans syndrome are medication, oxygen therapy, and lung transplant. Medication manages bronchiolitis obliterans syndrome (BOS) by controlling inflammation, slowing disease progression, and improving lung function. It is diagnosed with several diagnoses, such as pulmonary function tests, imaging tests, lung biopsy, and others for different disease types, including acute bronchiolitis and chronic bronchiolitis obliterans syndrome, and is used by various end users, such as hospitals, specialty clinics, diagnostic centers, and others.

What Is The Bronchiolitis Obliterans Syndrome Market Growth Forecast?

The bronchiolitis obliterans syndrome market size is expected to see strong growth in the next few years. It will grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to transplant procedure growth, early detection technologies, personalized immunotherapy, specialty respiratory centers, long-term patient management. Major trends in the forecast period include increased monitoring post transplantation, growth of immunosuppressive therapies, expansion of early diagnostic testing, focus on long-term lung function preservation, rising demand for specialized pulmonary care.

Global Bronchiolitis Obliterans Syndrome Market Segmentation

1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant 2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis 3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome 4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users Subsegments: 1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents 2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy 3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation

What Are The Drivers Of The Bronchiolitis Obliterans Syndrome Market?

The growing number of lung transplantations is expected to propel the growth of the bronchiolitis obliterans syndrome market going forward. Lung transplantation is a surgical operation where a damaged or malfunctioning lung is replaced with a healthy lung from a donor to improve breathing. Lung transplantations are increasing due to advancements in surgical techniques that have significantly improved the success rates and reduced complications, making the procedure safer and more accessible for patients in need. Lung transplantation can effectively treat advanced bronchiolitis obliterans syndrome by replacing damaged lungs with healthy donor lungs, improving breathing and lung function. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, lung transplants had the largest proportional growth from 3,026 transplants in 2023 to 3,340 in 2024, an increase of 10.4 percent. Therefore, the growing number of lung transplants is driving the growth of the bronchiolitis obliterans syndrome industry. The increasing clinical trials are expected to propel the growth of the bronchiolitis obliterans syndrome market going forward. Clinical trials refer to research studies conducted in humans to evaluate the safety, efficacy, and effectiveness of medical interventions such as drugs, medical devices, procedures, or behavioral therapies. Clinical trials are rising due to increasing demand for personalized medicine, requiring more studies to validate targeted, gene-based therapies. Clinical trials support bronchiolitis obliterans syndrome treatment by testing new therapies aimed at easing inflammation and preserving lung function. They also enhance understanding of disease progression and treatment safety. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the number of industry-initiated clinical trials in the UK grew from 411 in 2022 to 426 in 2023, supported by a 16.5% increase in Phase III trials. Therefore, increasing clinical trials is driving the growth of the bronchiolitis obliterans syndrome industry.

Key Players In The Global Bronchiolitis Obliterans Syndrome Market

Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.

Global Bronchiolitis Obliterans Syndrome Market Trends and Insights

Major companies operating in the bronchiolitis obliterans syndrome market are focusing on developing advanced solutions such as at-home nebulized therapy to enhance medication adherence and slow disease progression through targeted, continuous treatment. At-home nebulized therapy involves using a nebulizer to transform liquid medication into a breathable mist, allowing direct delivery to the lungs. This convenient, self-administered treatment enables effective management of respiratory conditions from the comfort of home. For instance, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical company, launched ARINA-1, which received Food and Drug Administration (FDA) Fast Track Designation for aiming at preventing the progression of bronchiolitis obliterans syndrome (BOS) in patients with bilateral lung transplants. This regulatory milestone underscores ARINA-1’s potential to address a critical unmet medical need in transplant medicine. The Fast Track status enables more frequent communication with the FDA and prioritizes ARINA-1 for accelerated development and review, reflecting Renovion's commitment to advancing respiratory health through innovative, patient-focused therapeutics.

Regional Insights

North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Bronchiolitis Obliterans Syndrome Market?

The bronchiolitis obliterans syndrome market consists of revenues earned by entities providing services such as psychological counseling, patient monitoring and follow-up care, nutritional support, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The bronchiolitis obliterans syndrome market also includes sales of high-resolution CT (HRCT) scanner, oxygen concentrators, flexible bronchoscope, and invasive ventilators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bronchiolitis Obliterans Syndrome Market Report 2026?

The bronchiolitis obliterans syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bronchiolitis obliterans syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.